The Priority Review

Tag

Hematology

1 story

  1. Clinical trials

    Protagonist posts results of Phase 3 rusfertide study in polycythemia vera

    Protagonist Therapeutics, Inc. has posted results for VERIFY, a Phase 3 study of rusfertide in polycythemia vera. The record lists response for 32.9% of participants on placebo and 76.9% on rusfertide.